Abstract
Triple-negative breast cancer (TNBC) lacks targeted therapeutic options, and redox homeostasis and MYC-associated glutathione metabolism may represent a vulnerability. We evaluated the copper ionophore elesclomol and the HSP90 inhibitor luminespib, alone and combined, in MDA-MB-231 cells. Viability after treatment with elesclomol, luminespib, ganetespib or onalespib (0.05–0.2 µM) was measured via alamarBlue assay, and sensitivity was examined in the Genomics of Drug Sensitivity in Cancer (GDSC) dataset. Cells were then treated with elesclomol (0.05 µM), luminespib (0.1 µM) or both for apoptosis analysis (Annexin V-FITC/7-AAD), qPCR (c-MYC, GSS, CAT, SOD1, NOX1, NOS2, TGFB1) and multivariate, network and enrichment analyses. Elesclomol was the most potent compound, reducing viability to approximately 5% of control at 72 h versus 43% for luminespib. Quantification of Annexin V-positive cells across replicates showed an increase from 1.1% in the control group to 11.6% in the elesclomol group, 10.2% in luminespib and 13.2% in the combination groups, respectively (p < 0.0001). All treatments decreased c-MYC and increased GSS expression; elesclomol produced the largest increases in NOS2 and CAT, and the combination in NOX1. Principal component analysis separated the treatment groups (87.1% of variance on PC1 and PC2). Elesclomol had the most pronounced effects across assays. The observed decrease in c-MYC expression and increase in GSS expression suggest a potential association between MYC-related and glutathione-related pathways, warranting further mechanistic investigation.